Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.20    -0.40 (-0.30%)
Bid:
130.80
Ask:
131.20
Spread: 0.40 (0.306%)
Market Cap: £319.36m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn
15th Jun 202012:02 pmRNSPrice Monitoring Extension
12th Jun 202012:08 pmRNSSecond Price Monitoring Extn
12th Jun 202012:03 pmRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSResult of AGM
10th Jun 202012:08 pmRNSSecond Price Monitoring Extn
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSPositive Data from Vedanta IBD Clinical Studies
4th Jun 20207:00 amRNSPositive FDA Feedback on Follica
2nd Jun 20207:00 amRNSGelesis Approved to Market Plenity in Europe
28th May 20207:00 amRNSPRTC Targets COVID-19 Post-Recovery Complications
27th May 20207:00 amRNSPRTC to Present at Jefferies Virtual Conference
26th May 20201:05 pmRNSVor Appoints CFO Nathan Jorgensen
26th May 20207:00 amRNSPRTC Receives Another $45M from Affiliate Shares
22nd May 202012:02 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:00 amRNSPDMR Notification – Transfer From Trust
19th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 202012:02 pmRNSPrice Monitoring Extension
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th May 202012:07 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
4th May 202012:02 pmRNSPrice Monitoring Extension
23rd Apr 202012:07 pmRNSSecond Price Monitoring Extn
23rd Apr 202012:03 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSAkili ADHD Treatment Now Available in US
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 202012:07 pmRNSSecond Price Monitoring Extn
21st Apr 202012:02 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSPRTC to Present at Virtual Needham Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.